Enriching amnestic mild cognitive impairment populations for clinical trials: Optimal combination of biomarkers to predict conversion to dementia

Journal of Alzheimer's Disease

Volumn 32, Issue 2, 2012, Pages 373-385

  Yu, Peng ^a   Dean, Robert A ^a   Hall, Stephen D ^a   Qi, Yuan ^b   Sethuraman, Gopalan ^a   Willis, Brian A ^a   Siemers, Eric R ^a   Martenyi, Ferenc ^a   Tauscher, Johannes T ^a   Schwarz, Adam J ^a  

^a ELI LILLY AND COMPANY   (United States)

^b Purdue University   (United States)

Author keywords

Alzheimer's disease; apolipoprotein E; biomarker; cerebrospinal fluid; conversion; FDG PET; magnetic resonance imaging; mild cognitive impairment; prodromal; progression

Indexed keywords

APOLIPOPROTEIN E; BIOLOGICAL MARKER; FLUORODEOXYGLUCOSE F 18;

AGED; ALZHEIMER DISEASE; ARTICLE; BAYES THEOREM; CEREBROSPINAL FLUID; COGNITION; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL;

EID: 84867502641     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2012-120832     Document Type: Article

References (49)

1. PetersenRC(2004) Mild cognitive impairment as a diagnostic entity. J Int Med 256, 183-194.
2. Mitchell AJ, Shiri-Feshki M (2009) Rate of progression o mild cognitive impairment to dementia - meta-analysis of 41 robust inception cohort studies. Acta Psychiatric Scand 119, 252-265.
3. Fagan AM, Roe CM, Xiong C, Mintun MA,Morris JC, Holtzman DM (2007) Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 64, 343-349.
4. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK vdFW, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Ros'en E, Aarsland D, Visser PJ, Schr̈oder J, Marcusson J, de Leon M, Hampel H, Scheltens P, Pirttil̈a T, Wallin A, J̈onhagen ME, Minthon L, Winblad B, Blennow K (2009) CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 302, 385-393.
5. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM, Trojanowski JQ (2009) Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 65, 403-413.
6. Engelborghs S, De Vreese K, Van de Casteele T, Vanderstichele H,Van Everbroeck B, Cras P, Martin JJ,Vanmechelen E, De Deyn PP (2008) Diagnostic performance of a CSFbiomarker panel in autopsy-confirmed dementia. Neurobiol Aging 29, 1143-1159.
7. Sunderland T, Linker G, Mirza N, Putnam KT, Friedman DL, Kimmel LH, Bergeson J, Manetti GJ, Zimmermann M, Tang B, Bartko JJ, Cohen RM (2003) Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 289, 2094-2103.
8. Visser PJ, Verhey F, Knol DL, Scheltens P, Wahlund LO, Freund-Levi Y, Tsolaki M, Minthon L, Wallin AK, Hampel H, Burger K, Pirttila T, Soininen H, Rikkert MO, Verbeek MM, Spiru L, Blennow K (2009) Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: A prospective cohort study. Lancet Neurol 8, 619-627.
9. Blennow K, Hampel H,Weiner M, Zetterberg H (2010) Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 6, 131-144.
10. Snider BJ, Fagan AM, Roe C, Shah AR, Grant EA, Xiong C, Morris JC, Holtzman DM (2009) Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type. Arch Neurol 66, 638-645.
11. Jack CR Jr, Petersen RC, Xu YC, Waring SC, O'Brien PC, Tangalos EG, Smith GE, Ivnik RJ, Kokmen E (1997) Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease. Neurology 49, 786-794.
12. Bobinski M, de Leon MJ, Wegiel J, Desanti S, Convit A, Saint Louis LA, Rusinek H, Wisniewski HM (2000) The histological validation of post mortem magnetic resonance imaging-determined hippocampal volume in Alzheimer's disease. Neuroscience 95, 721-725.
13. Vemuri P, Whitwell JL, Kantarci K, Josephs KA, Parisi JE, Shiung MS, Knopman DS, Boeve BF, Petersen RC, Dickson DW, Jack CR Jr (2008) Antemortem MRI based Structural Abnormality Index (STAND)-scores correlate with postmortem Braak neurofibrillary tangle stage. Neuroimage 42, 559-567.
14. McDonald CR, Gharapetian L, McEvoy LK, Fennema- Notestine C, Hagler DJ Jr, Holland D, Dale AM, ADNI (2012) Relationship between regional atrophy rates and cognitive decline in mild cognitive impairment. Neurobiol Aging 33, 242-253.
15. Vemuri P, Wiste HJ, Weigand SD, Shaw LM, Trojanowski JQ, Weiner MW, Knopman DS, Petersen RC, Jack CR Jr (2009) MRI and CSF biomarkers in normal, MCI, and AD subjects: Predicting future clinical change. Neurology 73, 294-301.
16. Risacher SL, Shen L,West JD, Kim S, McDonald BC, Beckett LA, Harvey DJ, Jack CR Jr, Weiner MW, Saykin AJ, ADNI (2010) Longitudinal MRI atrophy biomarkers: Relationship to conversion in the ADNI cohort. Neurobiol Aging 31, 1401- 1418.
17. Jack CR Jr, Shiung MM, Weigand SD, O'Brien PC, Gunter JL, Boeve BF, Knopman DS, Smith GE, Ivnik RJ, Tangalos EG, Petersen RC (2005) Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI. Neurology 65, 1227-1231.
18. Jack CR Jr, Petersen RC, Xu YC, O'Brien PC, Smith GE, Ivnik RJ, Boeve BF, Waring SC, Tangalos EG, Kokmen E (1999) Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology 52, 1397-1403.
19. Mosconi L, Berti V, Glodzik L, Pupi A, De Santi S, de Leon MJ (2010) Pre-clinical detection of Alzheimer's disease using FDG-PET, with or without amyloid imaging. J Alzheimers Dis 20, 843-854.
20. Haense C, Herholz K, Jagust WJ, Heiss WD (2009) Performance of FDG PET for detection of Alzheimer's disease in two independent multicentre samples (NEST-DD and ADNI). Dement Geriatr Cogn Disord 28, 259-266.
21. Beckett LA, Harvey DJ, Gamst A, Donohue M, Kornak J, Zhang H, Kuo JH (2010) The Alzheimer's Disease Neuroimaging Initiative: Annual change in biomarkers and clinical outcomes. Alzheimers Dement 6, 257-264.
22. Hampel H, Frank R, Broich K, Teipel SJ, Katz RG, Hardy J, Herholz K, Bokde AL, Jessen F, Hoessler YC, Sanhai WR, Zetterberg H, Woodcock J, Blennow K (2010) Biomarkers for Alzheimer's disease: Academic, industry and regulatory perspectives. Nat Rev Drug Discov 9, 560-574.
23. Vemuri P, Gunter JL, Senjem ML, Whitwell JL, Kantarci K, Knopman DS, Boeve BF, Petersen RC, Jack CR Jr (2008) Alzheimer's disease diagnosis in individual subjects using structural MR images: Validation studies. Neuroimage 39, 1186-1197.
24. Desikan RS, Cabral HJ, Settecase F, Hess CP, Dillon WP, Glastonbury CM,WeinerMW, Schmansky NJ, Salat DH, Fischl B (2010) Automated MRI measures predict progression to Alzheimer's disease. Neurobiol Aging 31, 1364-1374.
25. McEvoy LK, Edland SD, Holland D, Hagler DJ Jr, Roddey JC, Fennema-Notestine C, Salmon DP, Koyama AK, Brewer JB, PS A, DaleAM(2010) Neuroimaging enrichment strategy for secondary prevention trials in Alzheimer disease. Alzheimer Dis Assoc Disord 24, 269-277.
26. Bakkour A, Morris JC, Dickerson BC (2009) The cortical signature of prodromal AD: Regional thinning predicts mild AD dementia. Neurology 72, 1048-1055.
27. DeCarli C, Frisoni GB, Clark CM, Harvey D, Grundman M, Petersen RC, Thal LJ, Jin S, Jack CR Jr, Scheltens P (2007) Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia. Arch Neurol 64, 108-115.
28. Hansson O, ZetterbergH, Buchhave P, Londos E, BlennowK, Minthon L (2006) Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: A follow-up study. Lancet Neurol 5, 28-234.
29. Zetterberg H,Wahlund LO, Blennow K (2003) Cerebrospinal fluid markers for prediction of Alzheimer's disease. Neurosci Lett 352, 67-69.
30. DeMeyer G, Shapiro F, Vanderstichele H, Vanmechelen E, Engelborghs S, DeDeyn PO, Coart E, Hansson O, Minthon L, Zetterberg H, Blennow K, Shaw L, Trojanowski JQ, ADNI (2010) Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol 67, 949-956.
31. Drzezga A, Grimmer T, Riemenschneider M, Lautenschlager N, Siebner H, Alexopoulus P, Minoshima S, Schwaiger M, Kurz A (2005) Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET. J Nucl Med 46, 1625-1632.
32. Mosconi L, Perani D, Sorbi S, Herholz K, Nacmias B, Holthoff V, Salmon E, Baron JC, De Cristofaro MT, Padovani A, Borroni B, Franceschi M, Bracco L, Pupi A (2004) MCI conversion to dementia and the APOE genotype: A prediction study with FDG-PET. Neurology 63, 2332-2340.
33. Stone DJ, Molony C, Suver C, Schadt EE, Potter WZ (2010) ApoE genotyping as a progression-rate biomarker in phase II disease-modification trials for Alzheimer's disease. Pharmacogenomics J 10, 161-164.
34. Brys M, Glodzik L, Mosconi L, Switalski R, De Santi S, Pirraglia E, Rich K, Kim BC, Mehta P, Zinkowski R, Pratico D, Wallin A, Zetterberg H, Tsui WH, Rusinek H, Blennow K, de Leo MJ (2009) Magnetic resonance imaging improves cerebrospinal fluid biomarkers in the early detection of Alzheimer's disease. J Alzheimers Dis 16, 351-362.
35. Galluzzi S, Geroldi C, Ghidoni R, Paghera B, Amicucci G, Bonetti M, Zanetti O, Cotelli M, Gennarelli M, Frisoni GB, TOMCWG (2010) The new Alzheimer's criteria in a naturalistic series of patients with mild cognitive impairment. J Neurol 257, 2004-2014.
36. Hinrichs C, Singh V, Xu G, Johnson SC, ADNI (2011) Predictive markers for AD in a multi-modality framework: An analysis of MCI progression in the ADNI population. NeuroImage 55, 574-589.
37. Walhovd KB, Fjell AM, Brewer J, McEvoy LK, Fennema- Notestine C, Hagler DJ, Jennings RG Jr, Karow D, Dale AM (2010) ADNI, Combining MR imaging, positron-emission tomography, and CSF biomarkers in the diagnosis and prognosis of Alzheimer disease. Am J Neuroradiol 31, 347-354.
38. Landau SM, Harvey D, Madison CM, Reiman EM, Foster NL, Aisen PS, Petersen RC, Shaw LM, Trojanowski JQ, Jack CR Jr,Weiner MW, Jagust WJ, ADNI (2010) Comparing predictors of conversion and decline in mild cognitive impairment. Neurology 75, 230-238.
39. Zhang D, Wang Y, Zhou L, Yuan H, Shen D, ADNI (2011) Multimodal classification of Alzheimer's disease and mild cognitive impairment. NeuroImage 55, 856-867.
40. Cui Y, Liu B, Luo S, Zhen X, Fan M, Liu T, Zhu W, Park M, Jiang T, Jin J, ADNI (2011) Identification of conversion from mild cognitive impairment to Alzheimer's disease using multivariate predictors. PLoS ONE 6, e21896.
41. Holland D, Brewer JB, Hagler DJ, Fennema-Notestine C, Dale AM, ADNI (2009) Subregional neuroanatomical change as a biomarker for Alzheimer's disease. Proc Natl Acad Sci U S A 106, 20954-20959.
42. Landau SM, Harvey D, Madison CM, Koeppe RA, Reiman EM, Foster NL, Weiner MW, Jagust WJ, ADNI (2011) Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging 32, 1207-1218.
43. Chen K, Langbaum JB, Fleisher AS, Ayutyanont N, Reschke C, Lee W, Liu X, Bandy D AG, Thompson PM, Foster NL, Harvey DJ, de Leon MJ,Koeppe RA, Jagust WJ,WeinerMW, Reiman EM, Alzheimer's Disease Neuroimaging EM, Initiative (2010) Twelve-month metabolic declines in probable Alzheimer's disease and amnestic mild cognitive impairment assessed using an empirically pre-defined statistical region-of-interest: Findings from the Alzheimer's Disease Neuroimaging Initiative. Neuroimage 51, 654-664.
44. Qi Y, Minka TP, Picard RW, Ghahramani Z (2004) Predictive automatic relevance determination by expectation propagation. Proceedings of Twenty-first International Conference on Machine Learning, p. 85. doi: 10.1145/1015330. 1015418.
45. Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ (2010) Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 9, 119-128.
46. Karow DS, McEvoy LK, Fennema-Notestine C, Hagler DJ Jr, Jennings RG, Brewer JB, Hoh CK, Dale AM (2010) Relative capability of MR imaging and FDG PET to depict changes associated with prodromal and early Alzheimer disease. Radiology 256, 932-942.
47. Teipel SJ, Born C, Ewers M, Bokde AL, Reiser MF, M̈oller HJ, Hampel H (2007) Multivariate deformation-based analysis of brain atrophy to predict Alzheimer's disease in mild cognitive impairment. Neuroimage 38, 13-24.
48. Andreasen N, Blennow K (2005) CSF biomarkers for mild cognitive impairment and early Alzheimer's disease. Clin Neurol Neurosurg 107, 165-173.
49. Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O (2012) Cerebrospinal fluid levels of betaamyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry 69, 98-106.